We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » INSITE VISION SUBMITS NDA FOR AZASITE IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS WITH U.S. FDA
INSITE VISION SUBMITS NDA FOR AZASITE IN THE TREATMENT OF BACTERIAL CONJUNCTIVITIS WITH U.S. FDA
June 30, 2006
Thursday, InSite Vision, Inc., an ophthalmic products company, revealed the submission of a New Drug Application or NDA with the U.S. Food and Drug Administration for AzaSite indicated in the treatment of bacterial conjunctivitis. The submission includes positive results from the completed Phase 3 clinical trials, pre-clinical studies, chemistry, manufacturing, and controls. Trading Markets Live
